BioCentury
ARTICLE | Company News

Motif delays NDA for iclaprim in ABSSSIs

March 20, 2018 5:45 PM UTC

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) said it will delay submitting its NDA for iclaprim (MTF-100) to FDA until next quarter. The company had hoped to submit the NDA this quarter seeking the antibiotic's approval to treat acute bacterial skin and skin structure infections.

The company said it needs more time to "ensure a complete and high quality submission."...

BCIQ Company Profiles

Motif Bio plc

BCIQ Target Profiles

Dihydrofolate reductase